| Current: | |
| Cash and cash equivalents | 31.02M |
| Restricted cash | |
| Marketable securities, available for sale | |
| Taxes receivable | |
| Other receivables | |
| Prepaid and other assets | 283K |
| Total current assets | 31.33M |
| Property and equipment, net | 0 |
| Intellectual property, net | 34K |
| Other assets | |
| Total assets | 31.36M |
| Current: | |
| Accounts payable | 467K |
| Clinical trial expenses | 1K |
| Payroll and related | 344K |
| Accounting and legal fees | 441K |
| Severance | |
| Other | |
| Income taxes payable | |
| Total current liabilities | 2.77M |
| Common stock warrant liability | 7K |
| Other long term liabilities | |
| Total liabilities | 3.4M |
| Commitments | 0 |
| Series A preferred stock, $.01 par value; 50,000,000 shares authorized; 0 and 1,813,944 outstanding | 0 |
| Common stock, $.01 par value; 100,000,000 shares authorized; 26,399,764 and 38,605,483 issued and outstanding | 641K |
| Additional paid-in capital | 287.79M |
| Accumulated other comprehensive income | |
| Deficit accumulated during the development stage | |
| Total stockholders' equity | |
| Total liabilities and stockholders' equity | 31.36M |